Annovis Bio, Inc. (ANVS) is a Malvern, Pennsylvania-based Phase 3 clinical-stage biotechnology company developing the oral therapy buntanetap for Alzheimer's and Parkinson's disease. Its lead program, the 862-patient DUET-AD Phase 3 study in early Alzheimer's disease, is fully enrolled, with six-month topline data targeted for March 2027.
In Thursday's session, the stock traded at $0.7332, down 12.82% from the prior close of $0.8410 — a confirmed decline that erased the previous session's gain and pushed shares back toward their 52-week low of $0.6161. No new corporate announcement or analyst revision explained the drop; the selling appears to be a continuation of the post-earnings de-risking that has dominated the stock since mid-November.
No verified news or fundamental catalyst found for Thursday's session. There was no press release, no SEC filing, no analyst note, and no clinical update tied to the move, which came with volume running slightly below the recent average pace.
The most plausible technical explanation is a failed rebound and renewed supply in an illiquid, heavily traded micro-cap. The stock jumped 13.16% on Wednesday from $0.7432 to $0.8410, a one-day snapback typical of a name that has swung by double digits repeatedly. That bounce stalled immediately below the $0.85 area and reversed, a pattern consistent with short-term profit-taking rather than institutional accumulation. With a $45 million market cap and roughly 768,000 shares changing hands by late morning for about $590,000 in dollar volume, the order book is thin enough that modest selling moves the print several percentage points.
The fundamental backdrop remains the dominant weight. Third-quarter results on November 13 showed a net loss of $9.5 million, or $0.22 per share, alongside research and development expense of $15.8 million. More importantly, cash and equivalents stood at just $2.8 million at September 30, down from $19.5 million at the end of 2025, with stockholders' equity negative at approximately $13.2 million.
The company closed a $21.0 million underwritten public offering on November 6, with the board chairman personally investing $5 million. That capital is expected to fund operations through the March 2027 readout, but it came at a steep cost: shares outstanding now total 62.02 million, up roughly 88% year over year. Dilution of that magnitude on a sub-$1 stock tends to suppress rallies, and Wednesday's pop met the same fate.
On November 16, Roth Capital reiterated a Buy rating but slashed its price target to $3 from $7, flagging that the cash bridge to the Phase 3 six-month readout remains thin and adjusting for the higher share count and discount rate. Canaccord Genuity maintained a Buy with a $17 target the same day. The wide dispersion — targets now range from $3 to $17 — reflects genuine disagreement about financing risk rather than about the science.
Separately, the company disclosed on October 30 that NYSE had notified it of noncompliance with continued listing standards, because both its 30-day average market capitalization and stockholders' equity fell below $50 million. That notice adds a structural overhang and keeps financing decisions tied to listing requirements rather than purely to clinical strategy.
This week's Clinical Trials on Alzheimer's Disease conference in Boston delivered a split verdict for the field: Biogen reported that the lowest dose of diranersen slowed decline by 38% at two years in an open-label extension, while Priavoid's PRI-002 missed its efficacy endpoint and Eli Lilly ended development of mevidalen. Annovis presented three abstracts and has now received a second consecutive positive recommendation from the independent data and safety monitoring board to continue DUET-AD. For a stock priced largely on binary clinical risk, headline failures elsewhere in the category reinforce caution rather than invalidate the program.
Volume was not elevated. Roughly 768,000 shares had traded by late morning, a pace modestly behind the 30-day average of about 2.6 million and well short of the 20-day average near 3.6 million — consistent with drift and lack of conviction rather than a news-driven flush. The intraday range of roughly $0.72 to $0.83 represented about 13% of the prior close.
Technically, the stock sits far below its 50-day moving average near $1.07 and its 200-day near $1.79, and it is down more than 70% over the past 52 weeks. The rebound failed before reclaiming the $0.85–$0.90 zone that capped earlier recoveries, leaving the November 5 low of $0.6161 as the reference floor. Peer AVXL and other sub-$2 neuroscience names remain under similar pressure, so the weakness reads as sector-wide risk aversion layered on company-specific financing concerns.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This session scores 20 out of 100.
The news component is weak: nothing new was published Thursday, and the relevant fundamental items — quarterly results, the offering, the target cut, the exchange notice — are all several days old and already reflected in the price. The price component is moderate: at 12.82%, the decline was about 2.5 times the stock's average absolute daily move of roughly 5.1% over the past 60 sessions, and moves of this size or larger have occurred five times since mid-August. A routine-for-this-name move paired with no fresh catalyst produces a low score.
The next hard catalyst is the DUET-AD six-month topline, expected in March 2027, following the last patient visit on December 31, 2026 and database lock on February 8, 2027; an 18-month disease-modification analysis follows later. Enrollment in the Parkinson's open-label extension stands at 326 patients, with new enrollment closing in late January 2027.
Near term, investors will focus on NYSE compliance and whether the $21 million raise truly bridges to the readout, given the burn rate implied by third-quarter spending. Analysts remain split, with ratings clustered at Buy but targets ranging widely. Key risks include additional dilution, a further widening of losses, execution risk in the NDA preparation work with Weave Bio, and the possibility that data disappoints a field already digesting several setbacks this week.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. Strategies vary widely by approach, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions change. For traders navigating volatile micro-caps, reviewing the current leaders can add a disciplined, rules-based layer to the analysis. Explore the page to see which bots are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ANVS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ANVS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANVS's RSI Oscillator exited the oversold zone, 28 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where ANVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on ANVS as a result. In 69 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +34.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANVS advanced for three days, in 193 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ANVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.475) is normal, around the industry mean (3.596). P/E Ratio (-0.483) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ANVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders
Industry Biotechnology